Teva Asks Supreme Court To Weigh De Novo Review

Law360, New York (January 21, 2014, 5:53 PM EST) -- Teva Pharmaceuticals USA Inc. on Thursday asked the U.S. Supreme Court to review a ruling that invalidated some of the patents for its lucrative multiple sclerosis drug Copaxone, arguing the Federal Circuit had failed to give proper deference to the factual findings of district courts.

Teva said that the July ruling, which will allow Mylan Inc. and Sandoz Inc. to launch generic versions of the drug in May, shows that the Federal Circuit's long-standing rule of reviewing factual findings made during claim construction afresh on appeal,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.